Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kisanuki

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 1, 1993
[Anti-HIV compounds]Y Kiso, S Kisanuki
Biopharmaceutics & Drug Disposition|November 1, 1993
Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrationsA Kiriyama, T Mimoto, S Kisanuki, et al.
Chemical & Pharmaceutical Bulletin|November 1, 1991
KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimicT Mimoto, J Imai, S Tanaka, et al.
Chemical & Pharmaceutical Bulletin|August 1, 1992
Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatineT Mimoto, J Imai, S Kisanuki, et al.
Chemical & Pharmaceutical Bulletin|September 1, 1991
Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimicT Mimoto, J Imai, S Tanaka, et al.
Chemical & Pharmaceutical Bulletin|September 19, 2000
Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostereT Mimoto, N Hattori, H Takaku, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 1, 1993
[Anti-HIV compounds]Y Kiso, S Kisanuki
Biopharmaceutics & Drug Disposition|November 1, 1993
Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrationsA Kiriyama, T Mimoto, S Kisanuki, et al.
Chemical & Pharmaceutical Bulletin|November 1, 1991
KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimicT Mimoto, J Imai, S Tanaka, et al.
Chemical & Pharmaceutical Bulletin|August 1, 1992
Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatineT Mimoto, J Imai, S Kisanuki, et al.
Chemical & Pharmaceutical Bulletin|September 1, 1991
Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimicT Mimoto, J Imai, S Tanaka, et al.
Chemical & Pharmaceutical Bulletin|September 19, 2000
Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostereT Mimoto, N Hattori, H Takaku, et al.
Pageof 1